Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study

Etani, Yuki; Noguchi, Takaaki; Yukishima, Toshitaka; Kobayakawa, Tomonori; Kashii, Masafumi; Okamura, Gensuke; Goshima, Atsushi; Hirao, Makoto; Miura, Taihei; Kurihara, Takuya; Fukuda, Yuji; Sugimoto, Atsushi; Okada, Seiji; Nakata, Ken; Ebina, Kosuke

doi:https://doi.org/10.1016/j.bone.2025.117627

Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study

Etani, Yuki; Noguchi, Takaaki; Yukishima, Toshitaka et al.

Bone, 2025, 201, 117627

Number of Access:28（2025-12-03 12:37 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/102874

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
Bone_201	pdf	None	1.68 MB	25	2025.10.27

Creative Commons : Attribution - NonCommercial - NoDerivatives

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study
Creator	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 Scopus Author ID 57209857251 57209857251 CreatorName Etani, Yuki
	NRID 1000050812294 1000050812294 ORCID 0000-0001-9938-6780 0000-0001-9938-6780 researchmap permalink takaakinoguchi takaakinoguchi Scopus Author ID 56797347500 56797347500 CreatorName Noguchi, Takaaki
	CreatorName Yukishima, Toshitaka
	CreatorName Kobayakawa, Tomonori
	NRID 1000000576910 1000000576910 CreatorName Kashii, Masafumi
	CreatorName Okamura, Gensuke
	CreatorName Goshima, Atsushi
	NRID 1000010527708 1000010527708 CreatorName Hirao, Makoto
	CreatorName Miura, Taihei
	CreatorName Kurihara, Takuya
	CreatorName Fukuda, Yuji
	CreatorName Sugimoto, Atsushi
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 CreatorName Okada, Seiji
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 CreatorName Nakata, Ken
	NRID 1000070612076 1000070612076 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 CreatorName Ebina, Kosuke
Subject	Bone mineral density
	Bone turnover marker
	Denosumab
	N-terminal type I procollagen propeptide
	Romosozumab
	Teriparatide
Description	Etani Y., Noguchi T., Yukishima T., et al. Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study. Bone 201, 117627 (2025); https://doi.org/10.1016/j.bone.2025.117627.
Abstract	Purpose: To investigate the impact of baseline total N-terminal propeptide of procollagen (PINP) levels on increases in bone mineral density (BMD) after treatment with romosozumab (ROMO), teriparatide (TPTD), and denosumab (DMAb) in patients with treatment naïve primary osteoporosis. Methods: This multicenter, retrospective cohort study included 462 treatment-naïve patients (88.7 % female; mean age, 75.5 years; baseline BMD T-scores: lumbar spine [LS], −3.0; total hip [TH], −2.7) who initiated treatment with ROMO (n = 310), TPTD (n = 70), or DMAb (n = 82). Patients were stratified by baseline total PINP levels into low (≤ 70.1 μg/L) and high (> 70.1 μg/L) groups. After adjusting for baseline characteristics using inverse probability of treatment weighting, changes in BMD were evaluated at 12 months. Results: In the low PINP group, increases in LS BMD were similar between ROMO and TPTD; in the high PINP group, ROMO led to greater increases in LS BMD than TPTD. ROMO resulted in greater increases in TH BMD than TPTD, regardless of PINP level. Compared with DMAb, ROMO resulted in greater increases in LS BMD and TH BMD in the low PINP group, whereas no significant differences were observed in the high PINP group. Conclusion: ROMO demonstrated robust increases in both LS and TH BMD across all PINP levels. TPTD led to increases in LS BMD comparable to those with ROMO in the low PINP group. DMAb led to increases in both LS and TH BMD comparable to those with ROMO in the high PINP group.
Publisher	Elsevier Inc.
Source Title	Bone
Volume (Issue)	201
Page	117627
Date of Issued	2025-12-01
Language	English
Handle URL	https://hdl.handle.net/11094/102874
PISSN	87563282
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1016/j.bone.2025.117627
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Bone. 2025, 201, p. 117627
DC.title	Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study
DC.creator	Etani, Yuki
	Noguchi, Takaaki
	Yukishima, Toshitaka
	Kobayakawa, Tomonori
	Kashii, Masafumi
	Okamura, Gensuke
	Goshima, Atsushi
	Hirao, Makoto
	Miura, Taihei
	Kurihara, Takuya
	Fukuda, Yuji
	Sugimoto, Atsushi
	Okada, Seiji
	Nakata, Ken
	Ebina, Kosuke
DC.publisher	Elsevier Inc.
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-12-01
DC.identifier	https://doi.org/10.1016/j.bone.2025.117627
DC.subject	Bone mineral density
	Bone turnover marker
	Denosumab
	N-terminal type I procollagen propeptide
	Romosozumab
	Teriparatide
DC.description	Etani Y., Noguchi T., Yukishima T., et al. Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study. Bone 201, 117627 (2025); https://doi.org/10.1016/j.bone.2025.117627.
DCTERMS.abstract	Purpose: To investigate the impact of baseline total N-terminal propeptide of procollagen (PINP) levels on increases in bone mineral density (BMD) after treatment with romosozumab (ROMO), teriparatide (TPTD), and denosumab (DMAb) in patients with treatment naïve primary osteoporosis. Methods: This multicenter, retrospective cohort study included 462 treatment-naïve patients (88.7 % female; mean age, 75.5 years; baseline BMD T-scores: lumbar spine [LS], −3.0; total hip [TH], −2.7) who initiated treatment with ROMO (n = 310), TPTD (n = 70), or DMAb (n = 82). Patients were stratified by baseline total PINP levels into low (≤ 70.1 μg/L) and high (> 70.1 μg/L) groups. After adjusting for baseline characteristics using inverse probability of treatment weighting, changes in BMD were evaluated at 12 months. Results: In the low PINP group, increases in LS BMD were similar between ROMO and TPTD; in the high PINP group, ROMO led to greater increases in LS BMD than TPTD. ROMO resulted in greater increases in TH BMD than TPTD, regardless of PINP level. Compared with DMAb, ROMO resulted in greater increases in LS BMD and TH BMD in the low PINP group, whereas no significant differences were observed in the high PINP group. Conclusion: ROMO demonstrated robust increases in both LS and TH BMD across all PINP levels. TPTD led to increases in LS BMD comparable to those with ROMO in the low PINP group. DMAb led to increases in both LS and TH BMD comparable to those with ROMO in the high PINP group.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DC.format	102874
citation_title	Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study
citation_author	Etani, Yuki
	Noguchi, Takaaki
	Yukishima, Toshitaka
	Kobayakawa, Tomonori
	Kashii, Masafumi
	Okamura, Gensuke
	Goshima, Atsushi
	Hirao, Makoto
	Miura, Taihei
	Kurihara, Takuya
	Fukuda, Yuji
	Sugimoto, Atsushi
	Okada, Seiji
	Nakata, Ken
	Ebina, Kosuke
citation_publisher	Elsevier Inc.
citation_language	English
citation_date	2025-12-01
citation_journal_title	Bone
citation_volume	201
citation_firstpage	117627
citation_doi	https://doi.org/10.1016/j.bone.2025.117627
citation_public_url	https://hdl.handle.net/11094/102874

Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study

Link to primary information

Item Information

Show details